eCardio Diagnostics unveiled its eCardio Evolution, a near-time extended cardiac-monitoring platform that is currently in development, at the 2008 American College of Cardiology (ACC) Scientific Sessions in Chicago last week.
It allows the physicians to perform extended cardiac monitoring, which will be their choice in terms of time—typically seven to 14 to 28 days is now the norm, Robert Jordan, executive vice president at eCardio, told Cardiovascular Business News.
The company said that it focuses its product offering on monitoring devices and services that help optimize patient care, increase patient compliance and decrease the time to obtain an arrhythmia diagnosis.
“Our new device is going to be different because it is a single component, so the patient won’t be tethered to it at home. The patient will be allowed to conduct their daily activities and lead a normal lifestyle during whatever monitoring period has been designated for them,” Jordan noted.
“We believe that extended monitoring could go out as long as 28 days without a medical necessity letter being written by the physician. However, with implantable monitors, sometimes 28 days is not enough. With an implanted monitor, you’re looking at an event that occurs rarely, so with the extended monitoring period, a physician can write a letter to extend that period out another 30 days, thereby keeping the patient from having to receive an implantable device,” Jordan said.
Because eCardio is a web-based company, Jordan said that a physician could access data anywhere using the internet. “We are also investigating other unique technologies that will allow us to push critical events to a physician’s mobile device,” he said.
“From this last element of technology, the physician could call the patient from their mobile device, or call the lab directly. In this process, we have bypassed the step at the hospital, and in the attempts to gain real-time assessment, we want these physicians to be able to evaluate their patients from a monitor, reflecting the actual state of the patient,” according to Jordan.
“Also, our product will produce this result in near-time—we’re not talking in terms of an hour, we’re talking in terms of minutes,” Jordon said.
“What will distinguish Evolution is its ability to exchange the information remotely, and the patient doesn’t have to activate the device, which auto-detects arrhythmia and auto-sends it to the lab without the patient even having to be aware of this communication,” Jordan concluded.